Targeted vaccine adjuvants based on modified cholera toxin

Area of Science:

• Immunology
• Vaccinology
• Molecular Biology

Background:

• Development of safe and effective mucosal vaccines is crucial.
• Cholera toxin (CT) and its derivatives are explored as vaccine adjuvant vectors.
• Understanding immunomodulation mechanisms is key for vaccine design.

Purpose of the Study:

• To investigate immunomodulation strategies using targeted adjuvants for mucosal vaccine development.
• To differentiate the roles of enzymatic activity and B-cell targeting in immune responses.
• To elucidate the mechanisms by which adjuvants induce tolerance or IgA immunity.

Main Methods:

• Utilized cholera toxin (CT) and its derivatives, including enzymatically inactive forms (CTB, CTA1R7K).
• Constructed fusion proteins linking adjuvant components with B-cell targeting moieties (DD).
• Analyzed immune responses, including T cell expansion, B cell activation, and dendritic cell (DC) maturation, using gene expression profiling (Affymetrix).

Main Results:

• ADP-ribosyltransferase-active conjugates prevent tolerance and induce IgA immunity.
• Delivery of antigen (Ag) without ADP-ribosylation promotes tolerance.
• Enzymatic modulation of DCs is critical for CD4 T cell help in IgA B cell development.
• Inactive CTA1R7K-DD expands T cells but fails to support germinal center expansion.
• Adjuvants modulate co-stimulatory molecules (CD80, CD86, CD83, B7RP-1) on antigen-presenting cells (APCs).

Conclusions:

• Enzymatic activity of adjuvants dictates the dichotomy between tolerance and IgA immunity.
• Dendritic cell subsets are key players in the adjuvant-mediated immune response.
• Targeted adjuvants offer a rational design approach for safe and efficacious mucosal vaccines.